PT-141 is a development name for bremelanotide. In two pivotal trials of the product used for Vyleesi, premenopausal women with distressing, acquired and generalized low sexual desire reported better sexual desire and less distress about low desire than with placebo. The same trials did not show a significant increase in the number of satisfying sexual events. These are different outcomes, and none predicts what one person will experience.
Three outcomes from the same trial program
The two RECONNECT trials studied premenopausal women with acquired, generalized low desire causing distress (HSDD). They compared bremelanotide with placebo in a planned 24-week double-blind period. Of 1,267 women randomized, 1,247 entered the safety analysis and 1,202 the modified intention-to-treat efficacy analysis. These counts describe different analysis groups, not three independent studies. The trial report gives the model-based between-group differences below, using repeated measurements across the blinded period. Read the original report’s Methods and Results.
Read the units first. Desire and distress are questionnaire scores. A difference of 0.30 points is not a 30% improvement, a 30% chance of benefit, or an extra sexual event. Higher desire scores and lower distress scores represent improvement on their respective measures. The two scales have different units; their point differences cannot be ranked against each other.
Did people report more desire?
- What was measured
- The FSFI desire domain combines two questions about the frequency and level of desire. Its scale runs from 1.2 to 6; higher means more reported desire.
- Trial 301 / trial 302
- +0.30 / +0.42 points in change versus placebo, as reported by the paper’s model. Both comparisons were statistically significant.
- How to read it
- The average comparison favored bremelanotide. It is a change on this specific self-report scale, not proof of better erections, more encounters or a predictable personal response.
Did low desire feel less distressing?
- What was measured
- FSDS-DAO question 13 asks how often low desire bothered the participant. The scale runs from 0 to 4; lower means less reported bother.
- Trial 301 / trial 302
- −0.37 / −0.29 points in change versus placebo, as reported by the paper’s model. Both comparisons were statistically significant.
- How to read it
- This measures distress related to low desire. It does not establish that relationship problems, depression or every aspect of sexual function improved.
Were there more satisfying sexual events?
- What was measured
- Change in the number of satisfying sexual events was a secondary endpoint. An event count is different from desire, distress or the percentage of encounters rated satisfying.
- Trial 301 / trial 302
- No statistically significant difference in event-count change between treatment groups in either trial. The FDA label reports P = .76 and .70 for these comparisons.
- How to read it
- The positive desire and distress results do not establish an increase in satisfying-event count. The negative count result also does not erase what participants reported on the other two measures.
Numbers and endpoint hierarchy: Kingsberg et al., 2019, Results and Figure 1A–B; scale definitions and event-count comparisons: FDA prescribing information, revised October 2026, section 14 and Table 4. The paper’s modeled comparisons are not the label’s rounded, unadjusted arm-average changes.
Why “significant” does not give your chance of benefit
The first two measures were the prespecified co-primary endpoints. Their statistical significance addresses the trial comparison; it does not make the average difference a percentage of people helped. The paper also reports responder analyses using separately defined thresholds. Those are different calculations from the score differences shown here.
Follow-up matters too. In the label, end of study means the last visit during the blinded period; it is week 24 for participants who completed that period. Substantial numbers left early. The report’s analyses use repeated observations and missing-data methods, rather than representing every randomized woman’s completed 24-week outcome. Palatin sponsored the trials and participated in their design, execution, analysis and reporting; the paper discloses company ties and editorial support. These features belong in the interpretation, alongside the positive and negative findings.
Match the result to the person and product
The current U.S. Vyleesi label concerns premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD): low desire causing marked distress or interpersonal difficulty, not explained by another medical or psychiatric condition, relationship problems, or medication or drug effects. It is not indicated for men, postmenopausal women or sexual-performance enhancement. Diagnosis and individual suitability require clinical assessment. FDA label, section 1.
The pivotal studies used the bremelanotide injection product, not an arbitrary nasal spray or a product sold online under the PT-141 name. A shared ingredient name does not establish the same formulation, quality or results.
An earlier randomized crossover study involved 18 premenopausal women with a primary diagnosis of sexual arousal disorder and an experimental intranasal formulation. Its abstract reports some favorable subjective responses, but no significant difference in vaginal vasocongestion. That small, short-term experiment is not the same population, formulation or outcome test as RECONNECT. The full early paper was not available in this review. Diamond et al., 2006, original indexed abstract.
If the claim changes the population or preparation, the evidence must change with it. A claim about men, a nasal product or general performance needs matching human evidence. The two pivotal trials described here cannot supply that answer merely because the name PT-141 appears in both contexts. This is not a claim that no earlier studies in men exist.
Important risks belong beside the benefit
The current FDA label identifies several material risks. This selected summary is not a complete safety review or personal treatment advice. Read sections 4–8 of the prescribing information.
- Nausea and stopping treatment. In pooled placebo-controlled phase 3 trials, nausea occurred in 40.0% of Vyleesi-treated participants versus 1.3% with placebo. Overall discontinuation because of adverse reactions was 18% versus 2%. That latter rate is not the percentage who left for every possible reason. Flushing, headache, vomiting and injection-site reactions also occurred.
- Blood pressure and heart rate. The product can temporarily raise blood pressure and slow heart rate. It is contraindicated with uncontrolled hypertension or known cardiovascular disease; temporary changes are not automatically harmless.
- Darkened patches of skin or other tissue. Focal hyperpigmentation was reported, including on the face, gums and breasts. Resolution was not confirmed in every affected participant after stopping.
- Other medicines. Slower gastric emptying can alter absorption of oral medicines. The label specifically warns about reduced exposure to oral naltrexone and the risk of treatment failure. Medication decisions belong with the treating clinician, not an online protocol.
- Pregnancy uncertainty. Human data are insufficient to quantify risk; animal findings indicate potential fetal harm. Limited data do not establish safety.
These results do not verify the identity, purity or safety of an unverified product labeled PT-141. They also do not compare bremelanotide with every other treatment or establish a personal benefit–risk balance.
Sources3 linked sources
- Kingsberg et al. (2019): two RECONNECT phase 3 trials. Full original report read, including Methods, Results and sponsor disclosures. Linked supplements were not independently retrieved.
- FDA Vyleesi prescribing information, revised October 2026. Current product/population, endpoint definitions and comparisons, contraindications, warnings and selected adverse reactions. The later DailyMed posting inspected still embedded a March 2024 clinical revision; posting and prescribing-information revision are different dates.
- Diamond et al. (2006): experimental intranasal bremelanotide in 18 women. Original indexed abstract read; full paper not read. This additional source is retained in the separate hub profiles.